Obstructive Lung Disease and Low Lung Function in Adults in the United States

Data From the National Health and Nutrition Examination Survey, 1988-1994

David M. Mannino, MD; Robert C. Gagnon, MS; Thomas L. Petty, MD; Eva Lydick, PhD

Background: Obstructive lung disease (OLD) is an important cause of morbidity and mortality in the US adult population. Potentially treatable mild cases of OLD often go undetected. This analysis determines the national estimates of reported OLD and low lung function in the US adult population.

Methods: We examined data from the Third National Health and Nutrition Examination Survey (NHANES III), a multistage probability representative sample of the US population. A total of 20,050 US adults participated in NHANES III from 1988 to 1994. Our main outcome measures were low lung function (a condition determined to be present if the forced expiratory volume in 1 second–forced vital capacity ratio was less than 0.7 and the forced expiratory volume in 1 second was less than 80% of the predicted value), a physician diagnosis of OLD (chronic bronchitis, asthma, or emphysema), and respiratory symptoms.

Results: Overall a mean (SE) of 6.8% (0.3%) of the population had low lung function, and 8.5% (0.3%) of the population reported OLD. Obstructive lung disease (age-adjusted to study population) was currently reported among 12.5% (0.7%) of current smokers, 9.4% (0.6%) of former smokers, 3.1% (1.1%) of pipe or cigar smokers, and 5.8% (0.4%) of never smokers. Surprisingly, 63.3% (0.2%) of the subjects with documented low lung function had no prior or current reported diagnosis of any OLD.

Conclusions: This study demonstrates that OLD is present in a substantive number of US adults. In addition, many US adults have low lung function but no reported OLD diagnosis, which may indicate the presence of undiagnosed lung disease.

Arch Intern Med. 2000;160:1683-1689

Obstructive lung diseases (OLDs), which include chronic bronchitis, emphysema, and asthma, are the fourth most common cause of death in the United States and accounted for more than 109,000 deaths in 1997.1 Obstructive lung disease is the only major disease among the top 5 causes of death that is rising in prevalence and mortality.2 It is now estimated that nearly 16 million people in the United States have chronic bronchitis and emphysema, which is commonly referred to as chronic obstructive pulmonary disease (COPD).3 Costs of hospitalizations, physician visits, and consumption of health care resources for COPD were almost $1.5 billion in 1993.7 In addition, asthma may affect as many as 14.6 million people in the United States3,5 with associated direct medical costs of $6.0 billion in 1993.6

Because of the increase in prevalence and mortality of OLD, and the medical costs associated with them, it is important to identify patients and to treat them before they reach the symptomatic and costly stages of disease. The Lung Health Study showed that when patients with mild to moderate OLD quit smoking, their lung function declined only slightly over the next 5 years.7 In contrast, similar patients who continued to smoke had rapid rates of decline in lung function. In addition, the Lung Health Study showed a high incidence of mortality related to lung cancer, heart attack, and stroke in subjects with only mild to moderate airflow obstruction.7

Because a high proportion of OLD has eluded diagnosis, it is impossible to know the true prevalence of these diseases in the United States today. To estimate the magnitude of OLD in the United States, we analyzed data from the Third National Health and Nutrition Examination Survey (NHANES III) in an effort to determine how much of the US population might have low levels of lung function, OLD, and respiratory symptoms.
SUBJECTS AND METHODS

STUDY POPULATION

The NHANES III was conducted from 1988 to 1994 by the National Center for Health Statistics of the Centers for Disease Control and Prevention, Atlanta, Ga. In this study a stratified multistage clustered probability design was used to select a representative sample of the US population, yielding results that can be extrapolated to the entire US population. Study participants completed extensive questionnaires in the household and a comprehensive physical examination, including pulmonary function testing, either in the household or at a specially equipped mobile examination center. A total of 81 sites were included in the final sample. The study was approved by the National Center for Health Statistics Institutional Review Board.

SUBJECTS

Our study sample was limited to adults aged 17 years and older who classified themselves as whites or blacks, had pulmonary function testing performed in either the home or the mobile examination center, and had complete data on their race, smoking status, height, and presence of respiratory symptoms. Of the 20050 adult study participants, 543 were not of white or black race. 3355 did not have pulmonary function testing done. 8 were missing data on smoking status, race, or height, and 56 were missing data on 1 or more respiratory symptom. In addition, we excluded 4 women from the analysis who were current cigar or pipe smokers. After the exclusions, we had data from 16084 subjects available for our main analysis.

VARIABLE DEFINITION

The race of the participants was classified as either white or black and was determined by self-report on the questionnaire. We defined subjects as being current smokers, former smokers, pipe or cigar smokers, or never smokers based on their responses to series of questions. One had to have smoked more than 100 cigarettes to qualify as a former or current smoker and could not be currently smoking cigarettes to qualify as a pipe or cigar smoker. Former smokers were asked how old they were when they last smoked cigarettes. Subjects were asked “Has a doctor ever told you that you asthma?” and similar questions about chronic bronchitis and emphysema. Subjects with a positive response to the question about asthma or chronic bronchitis were also asked “Do you still have asthma?” and “Do you still have chronic bronchitis?” We considered subjects who responded that they currently had asthma or bronchitis, or that they had ever had a diagnosis of emphysema, to have a current diagnosis of OLD. We considered subjects with a positive response to a previous diagnosis of either chronic bronchitis or asthma, but a negative response to current disease, to have a past diagnosis of OLD. We classified subjects as having a symptom if they gave a positive response to the following questions involving specific symptoms (cough, phlegm, wheezing, and dyspnea): “Do you usually cough on most days for 3 consecutive months or more during the year?” “Do you bring up phlegm on most days for 3 consecutive months or more during the year?” “Have you had wheezing or whistling in your chest at any time in the past 12 months?” and “Are you troubled by shortness of breath when hurrying on level ground or walking up a slight hill?” If a subject had a positive response to any of these 4 symptoms, we considered that subject to have a respiratory symptom.

For most analyses, we stratified subjects into 6 age strata; 17 to 24 years, 25 to 44 years, 45 to 64 years, 65 to 74 years, 75 to 84 years, and 85 years and older. For use in logistic regressions we classified subjects as having or not having cardiovascular disease (positive response to physician-diagnosed stroke, myocardial infarction, or congestive heart failure); obesity (body mass index [BMI] >28, calculated as the weight in kilograms divided by the square of the height in meters); inactivity (based on self report as being less active than peers); and low socioeconomic status (based on family income below poverty level).

PULMONARY FUNCTION DATA

Using either a dry rolling seal spirometer in the mobile examination center or a portable spirometer in the home examination, spirometry was conducted on the examinees. Procedures for testing were based on the 1987 American Thoracic Society recommendations. To obtain acceptable protocol curves, examinees performed 5 to 8 forced expirations. We used published prediction equations for forced expiratory volume in 1 second (FEV1) to calculate the predicted FEV1 for whites and blacks, stratified by sex. We then determined the value of the FEV1 (as a percentage of the predicted value) for each subject. We defined subjects with an FEV1--forced vital capacity (FVC) ratio of less than 0.70 and an FEV1 less than 80% of their predicted value as having low lung function, and further divided this group into subjects with an FEV1 of 50% or more and those with less than 50% of their predicted value, corresponding to people with stage 1 vs stage 2 or 3 OLD.

ANALYSIS

We calculated all estimates using the sampling weight to represent adults aged 17 years and older in the United States. The purpose of these sampling weight calculations was to adjust for unequal probabilities of selection and to account for nonresponse. They were poststratified to the US population as estimated by the Bureau of the Census. For analyses, we used both SAS and SUDAAN, a program that adjusts for the complex sample design when calculating variance estimates. Most of our analyses stratified the data by race and sex, with further stratification by either smoking status or age. We also present data stratified by reported lung disease and level of lung function. In these strata and substrata, we determined the estimated national population, the mean FEV1 as percent predicted, the mean FEV1–FVC ratio, and the number and age-adjusted percentage of the population with low lung function. We used the 6 age classes noted above and the overall age distribution of the study participants to age-adjust our results. In addition, we determined the number and age-adjusted percentage of the population with past or current OLD and the age-adjusted percentage of the population with cough, phlegm, wheezing, dyspnea, or any respiratory symptom. We also determined the age-adjusted percentage of the population stratified by race, sex, and smoking status with low lung function but with no current diagnosis of any OLD. Finally, we modeled, using logistic regression, factors predicting subjects who were unable to perform pulmonary function testing, subjects with low lung function, and subjects with low lung function yet not reported OLD.
Our final data set contained 16084 subjects representing an estimated 169.3 million adults in the United States. Relative SEs for the data presented are less than 10%, except for data on pipe and cigar smokers, where the SEs are less than 35%. Among the population, an estimated 14.3 million (8.5%) had current OLD, and another 7.3 million (4.3%) had OLD in the past, but not currently (Table 1). The proportion of the population with past or current OLD varied by sex, race, and smoking status, with women reporting more disease than men, whites reporting more disease than blacks, and current or former smokers reporting more disease than never smokers (Table 1). Obstructive lung disease was present among 12.5% of current smokers, 9.4% of former smokers, 3.1% of pipe or cigar smokers, and 5.8% of never smokers (all age-adjusted to study population). Former smokers were, on average, older than never and current smokers (Table 1). Mean level of lung function, either as the FEV1-FVC ratio or FEV1 percent predicted, was always lower among current smokers, former smokers, and pipe or cigar smokers, compared with never smokers (Table 1). Among whites, the reported COPD component of OLD generally increased with age, while among blacks this trend was less apparent (Figure 1).

Subjects frequently reported more than 1 OLD. For example, 25.0% of subjects with current bronchitis reported that they had current asthma, and 34.3% of subjects with current asthma reported that they had current chronic bronchitis. Similarly, 19.4% of the subjects with emphysema reported that they had current asthma, and 25.0% of the subjects with emphysema reported that they had current chronic bronchitis. Among subjects who reported having been at some point diagnosed with asthma, 63.7% reported current asthma, and 58.3% of subjects who reported having been at some point diagnosed with chronic bronchitis also reported a current diagnosis.

Pulmonary function testing was not obtained on 3355 of the original 20050 subjects. The significant predictors of not having testing done were the presence of cardiovascular disease (odds ratio [OR], 1.4; 95% confidence interval [CI], 1.2-1.7) and age (OR, 1.9; 95% CI, 1.4-2.5 for those aged 65-74 years; OR, 2.9; 95% CI, 2.3-3.8 for those aged 75-84 years; and OR, 5.3; 95% CI, 3.8-7.3 for those aged 85 years and older, compared with those aged 17-24 years). Overall, 6.8% of the population, or an estimated 11.5 million people had low lung function (Table 2). An additional 7.2% of the population had an FEV1-FVC ratio of less than 0.7 but an FEV1 greater than 80% of the predicted value. Significant predictors of low lung function included current smoking (OR, 4.3; 95% CI, 3.2-5.7), former smoking (OR, 2.0; 95% CI, 1.5-2.5), pipe or cigar smoking (OR, 2.7; 95% CI, 1.4-5.0), current OLD (OR, 5.4; 95% CI, 4.1-7.0), prior OLD (OR, 1.8; 95% CI, 1.0-3.0), and age (ORs increased from 2.1 for those aged 25 to 44 years to 21.0 for those aged 85 years and older, compared with 17- to 24-year-olds, all CIs significant). Moderate to severe lung obstruction (FEV1 less than 50% of the predicted value and an FEV1-FVC ratio of less than 0.7) was more common among current and former smokers and among people aged 45 years and older (Figure 2 and Figure 3). Overall, 1.5% of the population, or an estimated 2.6 million people, had an FEV1 of less than 50% of the predicted value, including an estimated 900000 people with an FEV1 of less than 35% of the predicted value. Lower levels of lung function were associated with higher levels of reported symptoms (Table 3).

Current and former smokers reported respiratory symptoms more frequently than never smokers (Table...
Reporting of symptoms varied across disease strata (Table 3). Among subjects with low lung function, 66.1% reported at least 1 respiratory symptom (Table 3), compared with 34.4% of subjects with normal pulmonary function. There was a great deal of overlap between subjects reporting respiratory symptoms, those with low lung function, and those with current or prior OLD (Figure 4). Overall, 63.3% of the population with low lung function did not have a current diagnosis of OLD. Even among subjects with moderate to severe pulmonary impairment, as indicated by an FEV1 of less than 50% of the predicted value, 44.0% did not have a current diagnosis of OLD. Across sex, race, and smoking categories this proportion ranged from 40% to 88% (Figure 5). People with a past diagnosis of obstructive lung disease accounted for a small proportion of this group of subjects not currently diagnosed (Figure 5). The only significant predictors of low lung function without a current diagnosis of OLD were current smoking (OR, 1.6; 95% CI, 1.0-2.5), inactivity (OR, 0.6; 95% CI, 0.4-0.9), and cardiovascular disease (OR, 0.5; 95% CI, 0.3-0.7).

These data show that low lung function and OLD occur commonly in a nationally representative sample of the US population. Low lung function is found in more than 10% of the population over age 45 years, but is not associated with reported current OLD 63.3% of the time. This finding is important, because when these patients can be identified in early and less symptomatic stages of disease, interventions can be expected to alter the course and prognosis of disease. Clearly, smoking cessation is the most important feature in management and is apt to be beneficial when it is accomplished at an early age with only mild evidence of airflow obstruction. While the finding of low lung function does not by itself diag-
tends to be a progressive disease, with relentless decline in lung function and resultant morbidity and mortality beginning in the fifth or sixth decade of life. Preventing or forestalling this burden of disease may be possible through aggressive smoking cessation and, perhaps, medications that may improve baseline lung function. The search for other drugs to modulate the inflammatory processes incident to the pathogenesis of COPD is also ongoing.27-34

This survey is subject to several limitations that affect the interpretation of these results. The entire medical history, including the previous and current diagnoses, the respiratory symptoms, and the smoking histories, were entirely self-reported. It is possible that subjects may have underreported or overreported in any of these categories. For instance, we found that only 33.9% and 25.6% of subjects with COPD reported cough and phlegm, respectively. While the criteria for a positive response to these questions were stringent, this may indicate that either symptom or disease reporting was inaccurate. Another limitation was that current smokers who could be misclassified as former smokers. In our analyses, however, many of our findings were consistent with known relationships between respiratory disease, respiratory symptoms, and lung function, suggesting that any

---

Table 2. Characteristics of Participants With Low Lung Function, Stratified by Race, Sex, and Smoking Status*  

<table>
<thead>
<tr>
<th>Race/Sex</th>
<th>Smoking Status</th>
<th>Estimated Population</th>
<th>Low Lung Function, %†</th>
<th>Cough, %†</th>
<th>Phlegm, %†</th>
<th>Wheezing, %†</th>
<th>Shortness of Breath, %†</th>
<th>No. of Participants With Any Symptom</th>
<th>Any Symptom, %†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Black/F</td>
<td>Current smoker</td>
<td>2 954 000</td>
<td>184 000</td>
<td>8.6</td>
<td>8.0</td>
<td>9.0</td>
<td>19.9</td>
<td>33.1</td>
<td>126 000 43.5</td>
</tr>
<tr>
<td></td>
<td>Former smoker</td>
<td>1 281 000</td>
<td>69 000</td>
<td>4.3</td>
<td>2.8</td>
<td>6.6</td>
<td>14.3</td>
<td>28.6</td>
<td>472 000 36.7</td>
</tr>
<tr>
<td></td>
<td>Never smoker</td>
<td>6 823 000</td>
<td>160 000</td>
<td>2.6</td>
<td>4.5</td>
<td>5.0</td>
<td>10.5</td>
<td>25.8</td>
<td>2 000 000 31.8</td>
</tr>
<tr>
<td>Black/M</td>
<td>Current smoker</td>
<td>3 337 000</td>
<td>273 000</td>
<td>11.6</td>
<td>10.9</td>
<td>9.7</td>
<td>19.0</td>
<td>21.7</td>
<td>1 190 000 38.1</td>
</tr>
<tr>
<td></td>
<td>Former smoker</td>
<td>1 559 000</td>
<td>150 000</td>
<td>8.4</td>
<td>4.4</td>
<td>5.6</td>
<td>10.8</td>
<td>14.2</td>
<td>409 000 24.3</td>
</tr>
<tr>
<td></td>
<td>Pipe or cigar smoker</td>
<td>260 000</td>
<td>32 000</td>
<td>7.1</td>
<td>5.4</td>
<td>3.7</td>
<td>15.0</td>
<td>28.8</td>
<td>124 000 40.2</td>
</tr>
<tr>
<td></td>
<td>Never smoker</td>
<td>3 771 000</td>
<td>116 000</td>
<td>4.8</td>
<td>4.1</td>
<td>4.3</td>
<td>8.8</td>
<td>14.5</td>
<td>701 000 21.5</td>
</tr>
<tr>
<td>White/F</td>
<td>Current smoker</td>
<td>19 770 000</td>
<td>2 187 000</td>
<td>13.6</td>
<td>20.6</td>
<td>16.0</td>
<td>31.1</td>
<td>38.7</td>
<td>11 360 000 57.4</td>
</tr>
<tr>
<td></td>
<td>Former smoker</td>
<td>16 260 000</td>
<td>2 152 000</td>
<td>6.8</td>
<td>6.5</td>
<td>4.1</td>
<td>15.3</td>
<td>25.7</td>
<td>6 240 000 35.5</td>
</tr>
<tr>
<td></td>
<td>Never smoker</td>
<td>4 112 000</td>
<td>1 396 000</td>
<td>3.1</td>
<td>5.0</td>
<td>4.3</td>
<td>11.7</td>
<td>20.4</td>
<td>13 250 000 31.3</td>
</tr>
<tr>
<td>White/M</td>
<td>Current smoker</td>
<td>22 140 000</td>
<td>2 152 000</td>
<td>14.2</td>
<td>24.0</td>
<td>20.5</td>
<td>32.2</td>
<td>31.7</td>
<td>12 150 000 57.6</td>
</tr>
<tr>
<td></td>
<td>Former smoker</td>
<td>21 440 000</td>
<td>1 520 000</td>
<td>6.8</td>
<td>4.7</td>
<td>6.1</td>
<td>15.8</td>
<td>17.3</td>
<td>7 003 000 29.8</td>
</tr>
<tr>
<td></td>
<td>Pipe or cigar smoker</td>
<td>2 627 000</td>
<td>291 000</td>
<td>9.9</td>
<td>13.3</td>
<td>17.3</td>
<td>16.7</td>
<td>9.8</td>
<td>749 000 37.6</td>
</tr>
<tr>
<td></td>
<td>Never smoker</td>
<td>26 010 000</td>
<td>680 000</td>
<td>3.3</td>
<td>4.0</td>
<td>5.3</td>
<td>9.4</td>
<td>10.6</td>
<td>5 355 000 22.8</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>169 352 000</td>
<td>11 520 000</td>
<td>6.8</td>
<td>9.3</td>
<td>8.3</td>
<td>17.6</td>
<td>22.9</td>
<td>62 272 000 36.8</td>
</tr>
</tbody>
</table>

*Low lung function is a forced expiratory volume (FEV1) in 1 second–forced vital capacity (FVC) ratio of less than 0.70 and an FEV1 of less than 80% of the predicted value. All relative SEs are less than 35%. Data from the Third National Health and Nutrition Examination Survey, 1988-94.†Age adjusted to all study participants.
misreporting bias potentially present did not have a large effect on the results.

Another potential bias of this study design is that not everyone completed pulmonary function testing. It is possible that subjects unable to do pulmonary function testing were also more likely to have low levels of lung function, thus resulting in an underestimate in the burden of the prevalence of low lung function in the United States. Selection was limited to a noninstitutionalized, nonmilitary population, so it was not truly randomized to a general population. Only patients who were ambulatory and able to participate were studied, which might have created a selection bias.

Pulmonary function testing may provide an interventional opportunity in the United States. Since early intervention may alter the course and prognosis of OLD, it is important that all clinicians who encounter smokers and any patient with respiratory symptoms, particularly those over age 45 years, be able to make an accurate diagnosis. Previous studies have shown, though, that

### Table 3. Characteristics of Participants With Low Lung Function, Stratified by Reported Lung Disease and Level of Lung Function

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Estimated Population</th>
<th>No. of Participants With Low Lung Function</th>
<th>Low Lung Function, %</th>
<th>Cough, %</th>
<th>Phlegm, %</th>
<th>Wheezing, %</th>
<th>Shortness of Breath, %</th>
<th>No. of Participants With Any Symptom</th>
<th>Any Symptom, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD† and asthma</td>
<td>2 302 000</td>
<td>939 000</td>
<td>29.9</td>
<td>50.8</td>
<td>46.7</td>
<td>80.6</td>
<td>65.0</td>
<td>2 221 000</td>
<td>94.5</td>
</tr>
<tr>
<td>COPD only</td>
<td>5 989 000</td>
<td>1 791 000</td>
<td>17.4</td>
<td>33.9</td>
<td>25.6</td>
<td>57.8</td>
<td>48.3</td>
<td>5 110 000</td>
<td>83.8</td>
</tr>
<tr>
<td>Asthma only</td>
<td>6 073 000</td>
<td>1 002 000</td>
<td>19.2</td>
<td>13.9</td>
<td>11.1</td>
<td>66.9</td>
<td>45.5</td>
<td>4 928 000</td>
<td>80.6</td>
</tr>
<tr>
<td>Chronic bronchitis or asthma in the past</td>
<td>7 280 000</td>
<td>584 000</td>
<td>8.9</td>
<td>13.7</td>
<td>11.2</td>
<td>29.5</td>
<td>32.7</td>
<td>3 740 000</td>
<td>52.2</td>
</tr>
<tr>
<td>No COPD or Asthma</td>
<td>147 700 000</td>
<td>7 204 000</td>
<td>5.1</td>
<td>7.3</td>
<td>6.9</td>
<td>12.3</td>
<td>19.6</td>
<td>46 280 000</td>
<td>31.6</td>
</tr>
<tr>
<td><strong>Lung Function Category</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1–FVC &lt; 0.70 and FEV1 &lt; 50% of predicted value</td>
<td>2 456 000</td>
<td>2 456 000</td>
<td>100.0</td>
<td>41.2</td>
<td>32.7</td>
<td>63.6</td>
<td>65.4</td>
<td>2 175 000</td>
<td>79.0</td>
</tr>
<tr>
<td>FEV1–FVC &lt; 0.70 and FEV1 ≥ 80% of predicted value</td>
<td>9 066 000</td>
<td>9 066 000</td>
<td>100.0</td>
<td>14.6</td>
<td>15.4</td>
<td>42.6</td>
<td>40.0</td>
<td>5 482 000</td>
<td>60.1</td>
</tr>
<tr>
<td>FEV1–FVC &gt; 0.70 and FEV1 ≥ 50% of predicted value</td>
<td>12 170 000</td>
<td>12 170 000</td>
<td>0.0</td>
<td>17.5</td>
<td>12.2</td>
<td>28.8</td>
<td>25.6</td>
<td>5 681 000</td>
<td>50.8</td>
</tr>
<tr>
<td>FEV1–FVC &gt; 0.70 and FEV1 ≥ 80% of predicted value</td>
<td>145 600 000</td>
<td>145 600 000</td>
<td>0.0</td>
<td>7.9</td>
<td>7.2</td>
<td>15.2</td>
<td>21.5</td>
<td>48 940 000</td>
<td>34.4</td>
</tr>
<tr>
<td><strong>Total§</strong></td>
<td>169 352 000</td>
<td>11 521 000</td>
<td>6.8</td>
<td>9.3</td>
<td>8.3</td>
<td>17.6</td>
<td>22.9</td>
<td>62 272 000</td>
<td>36.8</td>
</tr>
</tbody>
</table>

*Low lung function is a forced expiratory volume (FEV1) in 1 second–forced vital capacity (FVC) ratio of less than 0.70 and an FEV1 of less than 80% of the predicted value. All relative SEs are less than 35%. Unless otherwise indicated, all data are age adjusted to all study participants. Data from the Third National Health and Nutrition Examination Survey, 1988-94.*

†COPD indicates chronic obstructive pulmonary disease.
‡By definition.
§Totals may not be exact because of rounding.

---

**Figure 4.** A proportional Venn diagram of the prevalence of low lung function (forced expiratory volume in one second [FEV1]–forced vital capacity [FVC] ratio of less than 0.70 and an FEV1 less than 80% of the expected value), current or past diagnosis of obstructive lung disease, and the presence of 1 or more respiratory symptoms. From the Third National Health and Nutrition Examination Survey, 1988-94.

**Figure 5.** The age-adjusted percentage of people with a forced expiratory volume in 1 second (FEV1)–forced vital capacity (FVC) ratio of less than 0.70 and an less than 80% of the expected value and either no diagnosis or a past diagnosis of obstructive lung disease, stratified by race, sex, and smoking status (current smokers [CS], former smokers [FS], pipe or cigar smokers [PCS], and never smokers [NS]). From the Third National Health and Nutrition Examination Survey, 1988-94.
symptoms alone are not adequate to diagnose COPD, and that spirometry may need to be more widely used to detect early disease.

The National Lung Health Education Program is a new health care initiative aimed at involving primary care physicians in the early identification and treatment of obstructive lung disease. The National Lung Health Education Program is promoting the widespread use of simple office spirometry to measure the FEV₁, FVC, and FEV₁/FVC ratio. The present study demonstrates that a significant proportion of the US population older than 45 years has low lung function, which may represent unrecognized and potentially treatable OLD. Spirometry remains the most efficient means of identifying and treating this population.

Accepted for publication, November 17, 1999.

Reprints: David M. Mannino, MD, National Center for Environmental Health, Centers for Disease Control and Prevention, 1600 Clifton Rd, MS E-17, Atlanta, GA 30333-3724 (e-mail: dmm6@cdc.gov).

REFERENCES

17. Wald NJ, Watt HC. Prospective study of effect of switching from cigarettes to pipes or cigars on mortality from three smoking-related diseases. BMJ. 1997;314:1860-1863.